Nuclea Diagnostic Laboratories, LLC

Company Our Vision – to empower patients and physicians with better ways to manage and care for chronic diseases. Our mission – to deliver more proactive, precise diagnostics to manage cancer and other chronic diseases. At the Core of Proactive Health Nuclea Biotechnologies delivers more proactive, personalized and precise diagnostics to empower physicians and patients with better ways to manage and care for chronic disease. A History of Innovation Since our founding in 2005, Nuclea has been focused on the development of IVD and RUO diagnostic assays and kits for the early detection and monitoring of biomarkers in oncology and endocrinology. Our proprietary discovery platforms and clinical research network have resulted in a collection of novel biomarkers and antibodies that continue to fill our assay pipeline. In 2013, Nuclea acquired Oncogene Sciences products, including the Serum HER-2 IVD ELISA diagnostic kit, considered the gold standard in testing for metastatic breast cancer. The Cutting Edge of Clinical Testing Nuclea is also a leading innovator in mass spec testing. At our CLIA labs based in Pittsfield and Cambridge MA (Cambridge CLIA lab starting in late 2015), we offer a range of fully validated and reimbursable CLIA tests for proteins associated with cancer and other chronic diseases. Our Cambridge facility now also offers a broad menu of state-of-the-art Research Use Only (RUO) mass spectrometry-based assays for serum or plasma proteins associated with diseases including cancer, endocrine malfunction, renal disease, neurodegenerative disease, cardiovascular disease, diabetes, obesity and metabolic syndrome. A More Precise, Personalized Way to Monitor Disease Because of the unique biomarkers in an individual’s proteome, proteomic testing delivers a personalized, real-time snapshot of disease. Nuclea is at the forefront of proteomics. Whether providing an assay, test kit, or clinical lab service, Nuclea continues to set the standard for excellence, quality and innovation in this rapidly growing field